Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
By P. Sonneveld, I. Schmidt-Wolf, B. van der Holt, Laila el Jarari, U. Bertsch, H. Salwender, S. Zweegman, E. Vellenga, A. Broyl, I. Blau and 18 more. Journal of Clinical Oncology, 2012
805 citations recorded by the source corpus.
Subfields: Hematology, Oncology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/1f254db35adf7022f8f83289fdd30d429a845f70
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
Citations in the corpus
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “Bortezomib administered every other week has been shown to improve OS, particularly in patients with del(17p).(128) Bortezomib-based maintenance is preferable for high-risk patients.”
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, background): “Bortezomib administered every other week has been shown to improve OS, particularly in patients with del (17p).(132) Maintenance with bortezomib plus lenalidomide is recommended for patients with high-risk myeloma.”